BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17707461)

  • 1. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome.
    Huang HY; Shariat SF; Sun TT; Lepor H; Shapiro E; Hsieh JT; Ashfaq R; Lotan Y; Wu XR
    Hum Pathol; 2007 Nov; 38(11):1703-13. PubMed ID: 17707461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder.
    Koga F; Kawakami S; Fujii Y; Saito K; Ohtsuka Y; Iwai A; Ando N; Takizawa T; Kageyama Y; Kihara K
    Clin Cancer Res; 2003 Nov; 9(15):5501-7. PubMed ID: 14654529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Hum Pathol; 2006 Dec; 37(12):1568-76. PubMed ID: 16949911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
    Shariat SF; Youssef RF; Gupta A; Chade DC; Karakiewicz PI; Isbarn H; Jeldres C; Sagalowsky AI; Ashfaq R; Lotan Y
    J Urol; 2010 May; 183(5):1744-50. PubMed ID: 20299037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.
    Ohtsuka Y; Kawakami S; Fujii Y; Koga F; Saito K; Ando N; Takizawa T; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1322-6. PubMed ID: 16686732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas.
    Moll R; Wu XR; Lin JH; Sun TT
    Am J Pathol; 1995 Nov; 147(5):1383-97. PubMed ID: 7485401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
    Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
    J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
    Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study.
    Bruins HM; Skinner EC; Dorin RP; Ahmadi H; Djaladat H; Miranda G; Cai J; Daneshmand S
    Urol Oncol; 2014 Jan; 32(1):24.e13-9. PubMed ID: 23395238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
    Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
    Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
    Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
    Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal origin of lymph node metastases in bladder carcinoma.
    Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
    Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
    Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy.
    Mitra AP; Alemozaffar M; Harris BN; Schuckman AK; Skinner EC; Daneshmand S
    Urology; 2014 Dec; 84(6):1420-6. PubMed ID: 25306479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.
    Sari A; Calli A; Gorgel SN; Altinboga AA; Kara C; Dincel C; Cakalagaoglu F
    Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):153-8. PubMed ID: 21623185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.